《美股業績》美國防部外判資料分析公司Palantir(PLTR.US)連續四季盈利 股價炒高20%
美國國防部外判資料分析公司Palantir(PLTR.US)公布第三季業績。季度純利7,151萬美元,對上年度同期虧損1.24億美元。每股季度攤薄盈利3美仙,經調整後為7美仙,市場預期為6美仙。季度收入按年升17%至5.58億美元。
公司預期第四季收入介乎5.99億至6.03億美元,市場預期為6億美元。公司表示,第三季旗下人工智能平台用戶升近2倍。
公司股價昨日(2日)急升20.4%報17.97美元。公司連續四季錄得盈利,被視為潛在納入標普500指數股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.